Phase II trial of regorafenib in patients with imatinib resistrant gastrointestinal stromal tumor

Trial Profile

Phase II trial of regorafenib in patients with imatinib resistrant gastrointestinal stromal tumor

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 11 Jan 2018

At a glance

  • Drugs Regorafenib (Primary)
  • Indications Gastrointestinal stromal tumours
  • Focus Therapeutic Use
  • Acronyms RESET for GIST
  • Most Recent Events

    • 06 Jan 2018 Planned End Date changed from 30 Sep 2018 to 5 Dec 2018.
    • 05 Dec 2017 Status changed from recruiting to active, no longer recruiting.
    • 05 Jan 2017 Planned End Date changed from 18 Jan 2017 to 30 Sep 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top